Milka Kamau
Psychiatric/Mental Health · Sherman, TXNPI 1144872706
Payments from drug & device makers
Across 217 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Brainsway USA Inc$882
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$316
- Neurocrine Biosciences, Inc.$307
- Lundbeck LLC$201
- Teva Pharmaceuticals USA, Inc.$177
- plus $1K from 18 others
What the payments were for
- Travel & lodging$88221%
- Food & beverage$3,26679%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- deep tms$882
How this compares
$4,148 in reported general payments places this provider in the 85th percentile of 2,724 psychiatric/mental health providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 28 | $284,606 |
| VraylarCariprazine Hcl | 112 | $165,445 |
| RexultiBrexpiprazole | 27 | $38,780 |
| TrintellixVortioxetine Hydrobromide | 73 | $36,882 |
| Risperdal ConstaRisperidone Microspheres | 13 | $26,932 |
| Aripiprazole | 118 | $5,100 |
| Quetiapine Fumarate | 277 | $3,310 |
| Vilazodone Hcl | 47 | $3,199 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 61 | $2,839 |
| Duloxetine Hcl | 180 | $2,543 |
| Buspirone Hcl | 150 | $1,900 |
| Bupropion XlBupropion Hcl | 127 | $1,789 |
| Zaleplon | 46 | $1,749 |
| Atomoxetine Hcl | 28 | $1,697 |
| Divalproex Sodium ErDivalproex Sodium | 54 | $1,575 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $307 | $284,60628 claims |
| AbbVieVraylar | $1,140 | $165,445112 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $160 | $38,78027 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $34 | $36,88273 claims |
| Almatica Pharma LLCSertraline Hcl | $74 | $49699 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Sherman
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
- Jaime Nelson DensonAustin$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.